The future leaves
signals in time.

A new clinical trial suggests that a simple daily fiber supplement could significantly reduce knee osteoarthritis pain and improve muscle strength. Researchers found that these benefits might be linked to changes in gut bacteria and the hormone GLP-1.

AI tools and software for protein and genome design now support natural language input. This allows users to specify the type of protein they want the AI to create.

According to STAT, Artiva is shutting down after two deaths occurred in a cell therapy trial for autoimmune disease. The report notes the recent deaths are setbacks for drug companies' interest in applying cancer therapy strategies to autoimmune diseases.

The FDA has provided new details on a quicker approval pathway for personalized gene therapies. Rare disease advocates welcomed the move, which is aimed at speeding access to treatments.

A nonprofit organization is resurrecting the lead gene therapy program of Bloomsbury Genetic Therapies. The U.K. gene therapy startup had previously announced its shutdown after dosing only one patient.

Scientists discovered that low testosterone and a high-fructose diet can worsen fatty liver disease in mice. Changes in gut bacteria appear to drive this harmful interaction, suggesting a potential new target for preventing liver damage.

Scientists found that JAK inhibitors, prescribed for rheumatoid arthritis and other inflammatory diseases, may weaken a crucial immune defense against influenza, COVID-19, and other infections; by suppressing genes that normally fight viruses, these widely used anti-inflammatory drugs may leave patients more vulnerable to infection.

Columnist Michael Le Page examines experimental treatments that aim to block an immune overreaction to proteins released by skin bacteria, a process that may contribute to acne, with the goal of preventing or reducing it; the treatments remain experimental.

In an opinion piece, Karen E. Knudsen and Othman Laraki write that cancer vaccines are finally here, but several challenges must be addressed now if the vaccines are to reach patients faster than BRCA testing did. The item is commentary and does not report trial results.

Scientists in the Netherlands may have uncovered a clue regarding why some brains resist Alzheimer's. Researchers found that a rare group of immature brain cells remains in people over 80, and their behavior differs significantly between those who develop dementia and those who remain cognitively healthy.

Mayo Clinic scientists have uncovered new insights into "zombie cells," aging cells that contribute to inflammation and disease. Seven studies identified new targeting strategies, including a natural compound found in tomatoes. In aging mice, experimental treatments reduced inflammation and improved physical and brain health.

A gene therapy linked to a boy's death reportedly had limited efficacy. The item provides no further details, such as the trial stage, the therapy's name, or the parties involved.

Nature Medicine issued an author correction to its article on toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma, described as a multicenter randomized phase 3 trial. The feed provides no details about the correction's content, so no findings can be summarized.

Nature Medicine published an item titled 'Metabolic heterogeneity of obesity.' The feed context is sparse and offers no details about the article's content, type, or findings, so no results can be summarized beyond the title.

Scientists have identified a hidden cause of inflammatory bowel disease: antibodies that disable the immune system's natural ability to control inflammation, potentially explaining severe illness in thousands of patients. The finding also solves a 30-year genetic mystery and could pave the way for more precise diagnoses and targeted treatments.

Per STAT+, Roche's KRAS-targeting drug divarasib notched a lung cancer win, with a Roche study producing one of the more impressive data sets presented at this year's ESMO meeting.

A Phase 3 trial involving a targeted drug developed by Merck and Kelun-Biotech showed that it reduced the risk of death by one-third in patients with advanced endometrial cancer.